"These results are encouraging with regards to the use of risankizumab and the IL-23 p19 class as a new therapeutic option in Crohn's disease," said Dana Lukin, MD, PhD, of Weill Cornell Medicine in New York City, who was not involved in this study. Meanwhile, the placebo group saw declines in deep and endoscopic remissions achieved during induction. Check out other logos starting with 'H' entertainment, first-person, games, half life 2 1 logo, half life 2 1 logo black and white, half life 2 1 logo png, half life 2 1 logo transparent, Half-Life, Half-Life 2, logos that start with 'H', shooter, video game logos. For clinical remission based on stool frequency/abdominal pain score, only the higher dose of the interleukin (IL)-23 blocker showed a significant improvement over placebo at 52 weeks, at 51.8% compared to 39.6% ( P=0.004), she said in a presentation at the American College of Gastroenterology virtual meeting.Įndoscopic response rates doubled with maintenance therapy by study end, at 47.1% and 46.5% with the lower and higher doses, respectively, versus 22% with placebo ( P<0.001 for both).ĭeep and endoscopic remissions continued to increase for patients given the higher maintenance dose of risankizumab, while these more stringent endpoints remained stable for patients receiving the lower dose.
0 kommentar(er)
